ABL Bio Corp.

In the top alliance by deal value, ABL Bio entered a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio’s blood-brain barrier shu

The last few years have been bittersweet for ABL Bio. After reaching a major deal with Sanofi in 2021, the South Korean biotech was excited because it was also discussing a potential tie-up with GSK

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daiichi Sankyo Tries Wayfinder’s

In the past few months, South Korean bioventures, including ABL Bio , have clinched a series of large-scale global out-licensing deals, dominating the transactions in the country so far this year. So